{"disease":{"id":"toripalimab","name":"toripalimab"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05669092","title":"A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":174,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT07086469","title":"Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":69,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06719700","title":"Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":47,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04709380","title":"Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":36,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05760053","title":"Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":33,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04627363","title":"HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04278222","title":"Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false},{"nct_id":"NCT04425824","title":"Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}